For pharmaceutical and life sciences firms, a case-by-case approach to information and content management has been prevalent for too long. It is inefficient and results in different parts of a business collating overlapping data, rendering the prospect of consolidating information more or less impossible. This is especially true of product and regulatory information in life sciences.
This case-by-case approach to information and content management poses a challenge to progress – especially when it comes to companies’ ambitions for innovation and process automation. In life sciences, as in most other industries, it is now a commonly-stated strategic aim for organisations to become more ‘data-driven’: able to react at speed and to predict, plan and pre-empt future scenarios using sophisticated intelligence gleaned from everyday data. That could be signals about potential issues with new products, alerts to emerging gaps in the market, or insight into what constitutes a successful regulatory submission – and the ability to skip straight to a more robust initial application, auto-filled with high-quality, pre-approved content.
The pursuit of this data-driven approach is driving life sciences and pharma firms to rethink the way they organise and manage routine information, and combine this with broader intelligence to create something much more useful and powerful than the sum of its parts.
Source : Pharmatimes